

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208 (b)(3)

John G. Bartlett, M.D.

Committees: Anti-Infective Drugs Advisory Committee and the
Drug Safety and Risk Management Advisory Committee

Meeting Dates: December 14-15, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the overall benefit to risk considerations for the approved product, Ketek (telithromycin), new drug application (NDA) 21-144, manufactured by Sanofi-Aventis with the current indications of acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community acquired pneumonia, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Unrelated Advisory Board Membership	4 Competing Firms	Less than \$10,001 per year per firm
Unrelated Speaking (past)	Competitor	from \$5,001-\$10,000 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

/s/
Signature of SGE

11/27/06
Date